<DOC>
	<DOCNO>NCT00031148</DOCNO>
	<brief_summary>This study determine safety efficacy keratinocyte growth factor ( KGF ) prevent acute graft-versus-host disease ( GVHD ) patient undergo allogeneic bone marrow ( BM ) peripheral blood progenitor cell ( PBPC ) transplantation .</brief_summary>
	<brief_title>Keratinocyte Growth Factor Prevent Acute GVHD</brief_title>
	<detailed_description>GVHD remain major complication allogeneic BM transplantation initiate condition recipient transplant host tissue damage . Research demonstrate gastrointestinal ( GI ) tract critical organ GVHD pathophysiology . Agents protect GI tract may provide prophylaxis cytokine cascade lead reduce incidence severity GVHD . KGF protein stimulate growth epithelial cell include GI tract . KGF protect GI tract , prevent GVHD , preserve donor T-cell function . Patients receive standard GVHD prophylaxis addition study drug . Overall GVHD grade weekly first 2 month transplant , every week Day 100 . Response therapy measure use severity index , physical exam , laboratory serum value .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criterion : Diagnosis hematological malignancy , include myelodysplastic syndrome . Eligible cyclophosphamide total body irradiation condition therapy busulphan cyclophosphamide condition therapy . Must 6/6 human leukocyte antigen ( HLA ) match family member donor . Women must postmenopausal , sterile , use effective contraception 1 month , , 2 month study . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Exclusion criterion : Tcell depletion GVHD prophylaxis . Active hepatitis . Preexistent inflammatory bowel disease require active therapy . Active uncontrolled infection . Prior bone marrow peripheral blood stem cell ( PBSC ) transplantation . Documented hypersensitivity rHuKGF . Prior enrollment study rHuKGF . HIVpositive . Pregnant nursing . Active chronic skin disease require therapy .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Keratinocyte growth factor</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>HLA Antigens</keyword>
	<keyword>Transplantation , Homologous</keyword>
	<keyword>Recombinant Proteins</keyword>
</DOC>